Lanraplenib (GS-9876) is a potent and selective oral inhibitor of spleen tyrosine kinase (SYK) with an IC50 of 9.5 nM. It is being developed for inflammatory diseases and has been shown to inhibit SYK in platelet GPVI signaling without affecting bleeding time in preclinical and clinical studies.
